Flerin et al., 2020 - Google Patents
Impact of immunometabolism on cancer metastasis: a focus on T cells and macrophagesFlerin et al., 2020
View PDF- Document ID
- 14476993973772820464
- Author
- Flerin N
- Pinioti S
- Menga A
- Castegna A
- Mazzone M
- Publication year
- Publication venue
- Cold Spring Harbor Perspectives in Medicine
External Links
Snippet
Despite improved treatment options, cancer remains the leading cause of morbidity and mortality worldwide, with 90% of this mortality correlated to the development of metastasis. Since metastasis has such an impact on treatment success, disease outcome, and global …
- 201000011510 cancer 0 title abstract description 116
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leone et al. | Metabolism of immune cells in cancer | |
| Le Bourgeois et al. | Targeting T cell metabolism for improvement of cancer immunotherapy | |
| Hossain et al. | Reinvigorating exhausted CD8+ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy | |
| Lau et al. | Metabolism in the tumor microenvironment | |
| Beckermann et al. | Dysfunctional T cell metabolism in the tumor microenvironment | |
| Yan et al. | Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity | |
| Reinfeld et al. | The therapeutic implications of immunosuppressive tumor aerobic glycolysis | |
| Wu et al. | Cancer-associated adipocytes as immunomodulators in cancer | |
| Flerin et al. | Impact of immunometabolism on cancer metastasis: a focus on T cells and macrophages | |
| Morandi et al. | A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation | |
| Porta et al. | Tumor‐associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy | |
| Hargadon | Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints | |
| Ng et al. | Heterodimeric IL15 treatment enhances tumor infiltration, persistence, and effector functions of adoptively transferred tumor-specific T cells in the absence of lymphodepletion | |
| Hou et al. | Targeted arginine metabolism therapy: A dilemma in glioma treatment | |
| EP2916858A1 (en) | Method for inducing il-2-free proliferation of gamma delta t cells | |
| Shi et al. | Specific inhibition of PI3Kδ/γ enhances the efficacy of anti-PD1 against osteosarcoma cancer | |
| Liu et al. | CAR-T therapy and targeted treatments: emerging combination strategies in solid tumors | |
| Katopodi et al. | Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization | |
| Ganjoo et al. | The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy | |
| Kumar et al. | Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma | |
| Pillai et al. | Is nuclear sirtuin SIRT6 a master regulator of immune function? | |
| Angka et al. | Perioperative arginine prevents metastases by accelerating natural killer cell recovery after surgery | |
| Hu et al. | Synergistic effect of adoptive immunotherapy and docetaxel inhibits tumor growth in a mouse model | |
| Xuekai et al. | Advances in reprogramming of energy metabolism in tumor T cells | |
| Xu et al. | Immunometabolism: signaling pathways, homeostasis, and therapeutic targets |